Cresemba
Payments companies reported to CMS as associated with Cresemba. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Cresemba, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Cresemba
These are the largest totals companies reported as associated with Cresemba. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Hana Safah | Baton Rouge, LA | Hematology & Oncology | $83,530.81 |
| Rajat Walia | Phoenix, AZ | Pulmonary Disease | $64,949.53 |
| Arthur Jeng | Sylmar, CA | Infectious Disease | $40,997.70 |
| Michael Schuster | New York, NY | Hematology & Oncology | $34,210.91 |
| Antonio Arrieta | Orange, CA | Pediatric Infectious Diseases | $30,547.29 |
| Marty Allen | Lexington, KY | Infectious Disease | $23,300.42 |
| Scott Beegle | Albany, NY | Internal Medicine | $22,587.07 |
| Claudia Espinosa | Tampa, FL | Pediatric Infectious Diseases | $21,863.22 |
| Ali Hassoun | Huntsville, AL | Infectious Disease | $15,484.07 |
| Simon Yau | Houston, TX | Pulmonary Disease | $14,338.32 |
Prescribed Cresemba?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.